December 2024 in “International Journal of Drug Delivery Technology” The new delivery method for dutasteride is more effective and has fewer side effects.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
2 citations
,
March 2016 in “Düşünen Adam” Switching from escitalopram to duloxetine improved hair loss.
February 2026 in “Archives of Dermatological Research” Microneedle-delivered polyglutamate effectively and safely improves hair growth in androgenetic alopecia.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
1 citations
,
June 2022 in “JCRPE” Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
January 2016 in “SHILAP Revista de lepidopterología” Switching from escitalopram to duloxetine helped stop hair loss.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
2 citations
,
November 2020 in “Der Hautarzt” A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
July 2025 in “Ultrasound in Medicine & Biology” 1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
3 citations
,
August 2024 in “British Journal of Dermatology” Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
407 citations
,
January 2008 in “Cochrane Database of Systematic Reviews” Glucocorticoid corticosteroids improve muscle strength in Duchenne muscular dystrophy but can cause side effects.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
8 citations
,
January 2024 in “Microorganisms” Dupilumab improves skin microbiome balance in atopic dermatitis patients.
8 citations
,
October 2019 in “Dermatologic Therapy” Bicalutamide improves hair density in women safely.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
April 2026 in “American Journal of Clinical Dermatology”